Eiger to seek FDA approval of progeria therapy

Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) intends to submit an NDA to FDA next year for lonafarnib to treat Hutchinson-Gilford progeria syndrome, an ultra-rare premature aging disease. The company said the NDA will be based on existing data showing a survival benefit in progeria patients, and Eiger does not expect to conduct additional clinical efficacy studies prior to the submission.